Canada’s Vaccine Industry Committee

vaccine industry collaborating to develop solutions for covid-19

Canada’s Vaccine Industry Committee (VIC) collectively recognizes the responsibility that we have in working closely with the Government of Canada to safeguard public health and mitigate the impact of COVID-19. The (VIC) is currently engaged with Health Canada and Public Health Agency of Canada to mobilize the full scope of our scientific and manufacturing resources to respond to the current crisis. Our focus is to maintain the current supply of vaccines for all vaccine preventable diseases in Canada. Vaccine Industry Committee members will continue to proudly play their part, and work closely with all levels of government, the research community and public agencies to develop solutions to address our current and future Canadian vaccine supply needs. As an industry, we are committed to dedicating and sharing our scientific expertise, technical skills and manufacturing capabilities to address this unprecedented global health crisis. We are proud to share current examples of our collaborative industry leadership.

Astrazeneca

AstraZeneca recently announced a landmark agreement to collaborate with the University of Oxford on the development and distribution of the University’s potential recombinant adenovirus vaccine (AZD1222) aimed at preventing COVID-19 infection. Additionally, through the company’s scientific expertise in infectious disease and proprietary antibody discovery technology, AstraZeneca has been working to identify monoclonal antibod¬ies that have the potential to recognize, bind to and neutralize the SARS-CoV-2 virus.

biodextris

A CDMO offering process and analytical development services for biological compounds including vaccines and adjuvants. Biodextris is currently exploring collaborative projects with our Nasal Mucosal Vaccine platform to create an effective SARS-COV2 vaccine to stop the spread of COVID19.

glaxoSmithkline (GSk)

GSK’s initial response to the outbreak of COVID-19 has been to make its vaccine adjuvant technology available to scientists and organisations working on candidate vaccines. GSK is currently working with five partner companies and research groups across the world. GSK is also entering the new collaborative research effort, the COVID-19 Therapeutics Accelerator. Learn more. 

iMV

IMV Inc. is developing a vaccine against the SARS-CoV2 based on its unique DPX platform that activates B and T cells responses, even in older or immunocompromised adults. Fully synthetic, DPX COVID-19 offers the potential for accelerated development and rapid, large-scale production. First patient should receive DPX-COVID-19 during summer 2020. Learn more.

JANSSEN

Johnson & Johnson, through its Janssen Pharmaceutical Companies, expects to initiate human clinical studies of its lead COVID-19 vaccine candidate at the latest by September 2020 and anticipates the first batches of a COVID-19 vaccine could be available for emergency use authorization in early 2021, a substantially accelerated timeframe in comparison to the typical vaccine development process. Learn more.

Medicago

Medicago, a biopharmaceutical company headquartered in Quebec City, began Phase 1 clinical trials in healthy adults for its plant-derived COVID-19 vaccine candidate in July. Medicago is also planning a Phase 2/3 trial to be initiated this October. The company successfully produced a Virus-Like Particle (VLP) of the coronovirus just 20 days after obtaining the SARSCoV-2 (virus causing the COVID-19 disease) gene back in March. Learn more.

merck

Merck makes a range of medicines and vaccines for infectious diseases. We are actively engaged in scientific efforts to develop safe and effective therapeutics and vaccines against COVID-19. We are also mobilizing our research partners and networks across Canada to help support COVID-19 related research efforts.

pfizer

Pfizer has outlined a five-point plan calling on the biopharmaceutical industry to collaborate to combat COVID-19. The plan is intended to help scientists bring forward therapies and vaccines to help protect humankind from the pandemic and prepare the industry to respond to future global health crises. As part of that plan, Pfizer and BioNTech are currently carrying out Phase 2b/3 clinical trials for BioNTech’s mRNA-based vaccine candidate BNT162, which is being developed to help prevent COVID-19 infection.

On August 5, 2020, Pfizer and BioNTech announced an agreement with the Canadian government to supply their BNT162 mRNA-based vaccine candidate against SARS-CoV2, subject to clinical success and regulatory approval, over the course of 2021. Pfizer Canada is currently working in parallel with Canadian stakeholders to define how this vaccine can be brought to the Canadian population.

Recently, alongside leading biopharmaceutical companies who are also conducting vaccine research and development, we’ve announced a historic pledge that outlines a united commitment to uphold the integrity of the scientific process as we work towards developing a potential vaccine for COVID-19 that puts patient safety and public health as top priorities.

Additionally, Pfizer is actively involved in the research of potential antiviral therapies.

sanofi pasteur

Will leverage previous development work for a SARS vaccine which may unlock a fast path forward for developing a COVID-19 vaccine. Sanofi will collaborate with the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response, expanding the company’s long-standing partnership with BARDA. More information can be found here.

seqirus

Seqirus is part of the CSL Group, which has partnered with the Coalition for Epidemic Preparedness Innovations (CEPI) and the University of Queensland in Australia to accelerate the development, manufacturing and distribution of a COVID-19 vaccine candidate, which is being developed using Seqirus’ well-established MF59® adjuvant technology. The company is also engaged with other academic partners and governments, applying our capabilities to further support the COVID-19 response. Learn more.

VALNEVA

Valneva, a specialty vaccine company focused on prevention against infectious diseases with major unmet medical needs, and Dynavax Technologies Corporation, a biopharmaceutical company focused on developing and commercializing novel vaccines, are collaborating to develop a highly purified inactivated vaccine candidate against the novel SARS-COV-2 coronavirus. Learn more.

VBI

VBI and the National Research Council of Canada (NRC) announced a collaborative research agreement to develop a broadly protective pan-coronavirus vaccine candidate including COVID-19. The vaccine builds on the safe and potent clinical history of VBI’s enveloped Virus Like Particle (eVLP) platform. Learn more.

VIRICA BIOTECH

Virica would like to collaborate with developers of virus-based vaccines who are looking to increase manufacturing yields. Virica will provide evaluation quantities of our VSe compounds under a material transfer agreement in order to facilitate the testing and use of our technology in vaccine production. We will work closely with partners to develop VSe formulations for their unique manufacturing processes and support regulatory submissions, where necessary. Learn more. 

VIDO-INTERVAC

Their scientists were the first in Canada to isolate the COVID-19 virus, in collaboration with PHAC and Sunnybrook and are developing a candidate vaccine for COVID-19. Recent vaccine results demonstrated the vaccine induced a strong immune response, generated neutralizing antibodies, and decreased virus in the upper respiratory tract to almost undetectable levels. VIDO-InterVac is excited by these results and are continuing to develop our vaccine towards regulatory approval.

Access by external groups to VIDO-InterVac’s containment level 3 facility is available through contract requests. Learn more.

Want to learn more about vaccine development and manufacturing in Canada? Click here for presentation.

For more information on vaccines in Canada, please see White paper series here.

Leadership in global health

Vaccine Industry Committee members are the leading vaccine manufacturers serving the Canadian market and early stage Canadian companies developing advanced vaccine technologies. The committee works to ensure a secure supply of vaccines for Canada, advocates for equitable access to vaccines for all Canadians, and promotes the value of immunization as one of the most cost-effective health interventions available.

Position Statement 
BIOTECanada’s Vaccine Industry Committee works to ensure a secure supply of vaccines for Canada, advocates for equitable access to vaccines for all Canadians, and promotes the value of immunization as one of the most cost-effective health interventions available.

The committee supports the WHO’s position of vaccines hesitancy being one of the top public health threats.

Vaccine hesitancy – the reluctance or refusal to vaccinate despite the availability of vaccines – threatens to reverse progress made in tackling vaccine-preventable diseases.
Vaccination is one of the most cost-effective ways of avoiding disease – it currently prevents 2-3 million deaths a year worldwide. (Reference)

We commit to working with our partner members on ensuring that Canadians have access to balanced information about the broad public health benefits of vaccination.

Primary public policy activities include:

  • Promoting the value of vaccines and importance of our industry
  • Ensuring adequate and timely funding mechanisms for new vaccines
  • Improving Canada’s procurement and safety of supply policies to ensure availability of vaccines
  • Implementation of the National Immunization Strategy
  • Ensuring Canada has an internationally competitive system for vaccine licensing
  • Improving the transparency and recommendation timelines of national advisory committees
  • Obtaining a satisfactory bar coding system with acceptable timelines

Want to learn more about vaccine development and manufacturing in Canada? Click here for presentation.

For more information about BIOTECanada’s Vaccine Industry Committee, contact Ron Boch.

VaCCINE INDUSTRY COMMITTEE MEMBERS